In this study we have taken advantage of the DNA minor-groove targeted cytotoxicity of the PDDs, and the highly specific targeting ability of antibodies, to provide the means to deliver these toxic PDD agents directly to melanoma cells through recognition of the CSPG4 cell surface antigen over-expressed by a high proportion of aggressive melanoma tumors. Here, CD53 is linked to melanoma.